NCT00781456 - A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches | Biotech Hunter

Enrollment

109

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Migraine

Interventions

DRUG

91-day Levonorgestrel Oral Contraceptive

91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.

DRUG

Placebo

1 tablet daily to match experimental arm

Trial Locations (22)

10022

Duramed Investigational Site, New York

15401

Teva Investigational Site, Uniontown

19114

Duramed Investigational Site, Philadelphia

20036

Duramed Investigational Site, Washington D.C.

23454

Duramed Investigational Site, Virginia Beach

27103

Teva Investigational Site, Winston-Salem

29201

Teva Investigational Site, Columbia

29926

Teva Investigational Site, Hilton Head

31406

Teva Investigational Site, Savannah

33409

Duramed Investigational Site, West Palm Beach

38120

Teva Investigational Site, Memphis

74105

Teva Investigational Site, Tulsa

75234

Duramed Investigational Site, Dallas

77054

Teva Investigational Site, Houston

78258

Duramed Investigational Site, San Antonio

91942

Teva Investigational Site, La Mesa

92108

Duramed Investigational Site, San Diego

92123

Teva Investigational Site, San Diego

97504

Teva Investigational Site, Medford

98105

Duramed Investigational Site, Seattle

94109-4841

Duramed Investigational Site, San Francisco

08817

Duramed Investigational Site, Edison